ALVR Split History

AlloVir (ALVR) has 1 split in our ALVR split history database. The split for ALVR took place on April 02, 2013. This was a 1 for 10 reverse split, meaning for each 10 shares of ALVR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as AlloVir conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ALVR split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AlloVir shares, starting with a $10,000 purchase of ALVR, presented on a split-history-adjusted basis factoring in the complete ALVR split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	10/17/2011
End date:	10/15/2021
Start price/share:	$9.80
End price/share:	$22.21
Dividends collected/share:	$0.00
Total return:	126.63%
Average Annual Total Return:	8.52%
Starting investment:	$10,000.00
Ending investment:	$22,656.62
Years:	10.00

About AlloVir

AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent viral diseases. Co.'s key product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. ALVR106 is Co.'s second multi-virus-targeted off-the-shelf VST product candidate that it developed to target respiratory diseases. ALVR109 is an allogeneic, off-the-shelf single virus-targeted cell therapy designed to target SARS-CoV-2. Co. is also developing ALVR107 designed to target hepatitis B, or HBV, infected cells and treat chronic HBV infections and ALVR108 to treat human herpesvirus-8. According to our ALVR split history records, AlloVir has had 1 split.